TY - JOUR
T1 - Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load
AU - Derosa, Giuseppe
AU - Maffioli, Pamela
AU - Ferrari, Ilaria
AU - Fogari, Elena
AU - D'Angelo, Angela
AU - Palumbo, Ilaria
AU - Randazzo, Sabrina
AU - Bianchi, Lucio
AU - Cicero, Arrigo Fg
PY - 2011/1/25
Y1 - 2011/1/25
N2 - The aim of this study was to evaluate the effects of acarbose on inflammatory biomarkers and insulin resistance in diabetic patients before and after a standardized oral fat load (OFL). Ninety six patients were assigned to take acarbose 50 mg three times a day and 92 to take placebo; after the first month acarbose was titrated to 100 mg three times a day. We evaluated the following parameters at the baseline, and after 1, 2 and 7 months: body mass index (BMI), glycemic control, fasting plasma insulin, post-prandial plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR), blood pressure, lipid profile, soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), high-sensitivity C reactive protein (Hs-CRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble E-selectin (sE-selectin). Furthermore, at the baseline and at the end of the study all patients underwent OFL, and an euglycemic hyperinsulinemic clamp to evaluate M value and total glucose requirement. Acarbose was better than placebo in improving glycemic and lipid profile, and HOMA-IR. Furthermore, acarbose gave a decrease of fasting plasma insulin, post-prandial insulin, s-ICAM-1, sVCAM-1, IL-6, and Hs-CRP, not observed with placebo, even if no significant differences between the two groups were observed. During the second OFL performed after the therapy with acarbose, we observed a significant decrease of all inflammatory parameters' peaks compared to the OFL administered at baseline. Acarbose was more effective than acarbose in reducing the post-OFL peaks of the various parameters included the inflammatory markers, after 7 months of therapy.
AB - The aim of this study was to evaluate the effects of acarbose on inflammatory biomarkers and insulin resistance in diabetic patients before and after a standardized oral fat load (OFL). Ninety six patients were assigned to take acarbose 50 mg three times a day and 92 to take placebo; after the first month acarbose was titrated to 100 mg three times a day. We evaluated the following parameters at the baseline, and after 1, 2 and 7 months: body mass index (BMI), glycemic control, fasting plasma insulin, post-prandial plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR), blood pressure, lipid profile, soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), high-sensitivity C reactive protein (Hs-CRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble E-selectin (sE-selectin). Furthermore, at the baseline and at the end of the study all patients underwent OFL, and an euglycemic hyperinsulinemic clamp to evaluate M value and total glucose requirement. Acarbose was better than placebo in improving glycemic and lipid profile, and HOMA-IR. Furthermore, acarbose gave a decrease of fasting plasma insulin, post-prandial insulin, s-ICAM-1, sVCAM-1, IL-6, and Hs-CRP, not observed with placebo, even if no significant differences between the two groups were observed. During the second OFL performed after the therapy with acarbose, we observed a significant decrease of all inflammatory parameters' peaks compared to the OFL administered at baseline. Acarbose was more effective than acarbose in reducing the post-OFL peaks of the various parameters included the inflammatory markers, after 7 months of therapy.
KW - Acarbose
KW - Euglycemic hyperinsulinemic clamp
KW - Inflammation
KW - Oral fat load
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=78650679019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650679019&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2010.11.015
DO - 10.1016/j.ejphar.2010.11.015
M3 - Article
C2 - 21118681
AN - SCOPUS:78650679019
VL - 651
SP - 240
EP - 250
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 1-3
ER -